Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzyme Engineering. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN120230725A reveals high-selectivity monooxygenase mutants for statin synthesis. Enables cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN102618513B details a robust biocatalytic route for API intermediates, offering high ee values and scalability without expensive cofactors.
Advanced P450 enzyme mutant technology enables efficient ursodeoxycholic acid production. Reduces costs and improves supply chain reliability for pharmaceutical intermediates.
Patent CN110577941B reveals mutated enzymes for high-purity chiral amine synthesis, offering cost reduction in pharmaceutical intermediate manufacturing via biocatalysis.
Patent CN121065123A reveals enhanced enzyme stability for chiral alcohol manufacturing cost reduction and supply reliability.
Patent CN120555388A reveals enhanced leucine dehydrogenase mutants for high-purity L-phenylglycine synthesis, offering significant supply chain and cost advantages.
Patent CN118879653A reveals high-efficiency DAAO mutant for L-glufosinate production. Achieves 99% conversion with reduced costs and enhanced supply chain reliability for global agrochemical manufacturers.
Patent CN111321193A reveals a novel enzymatic deracemization route for L-glufosinate. Discover cost-effective, high-yield manufacturing solutions for agrochemical intermediates.
Patent CN118685475A reveals high-yield NMN enzymatic method. Offers supply chain stability and cost reduction for nutraceutical manufacturers seeking reliable partners.
Patent CN114908129B reveals a novel dehydrogenase mutant for high-purity (R)-4-chloro-3-hydroxybutyric acid ethyl ester production, offering significant cost and supply chain advantages.
Patent CN113564151A reveals high-activity CsCE mutants enabling green lactulose synthesis with superior thermal stability and conversion rates.
Patent CN113652407B reveals a novel carbonyl reductase mutant enabling strict S-selectivity and enhanced activity for cost-effective chiral diol manufacturing.
Novel lipase mutant enables high-purity pregabalin intermediate production with improved activity and supply chain reliability for pharmaceutical manufacturing.
Novel transaminase mutants for chiral amine production. Enhanced stability at 55°C and pH 10. Cost-effective biocatalysis for pharma intermediates.
Patent CN108546698A reveals high-activity aspartase mutant for L-aspartic acid. Enables cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN116064451B reveals high-activity transaminase mutant. Enables cost reduction in pharmaceutical intermediates manufacturing with scalable enzymatic processes.
Patent CN115109759B reveals novel LsCR mutants for chiral alcohol synthesis. Achieve superior stability and yield for reliable pharmaceutical intermediate supply chains.
Patent CN111321193B details a novel enzymatic deracemization for high-purity L-glufosinate. Discover cost-effective biocatalytic solutions for herbicide manufacturing.
Patent CN1155716C reveals high-purity enzymatic synthesis. Offers cost reduction and supply reliability for pharmaceutical intermediates manufacturing globally.
Patent CN116904411A reveals mutant enzyme for efficient (R)-citronellal synthesis. Offers high ee value and conversion for reliable flavor and fragrance supplier needs.